{"url_path":"/sec/bngo/8-k/2026-05-14/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-14","source_url":"https://www.sec.gov/Archives/edgar/data/1411690/0001411690-26-000030-index.html","accession_number":"0001411690-26-000030","cik":"0001411690","ticker":"BNGO","issuer_name":"Bionano Genomics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1411690/0001411690-26-000030-index.html","primary_entity_key":"0001411690","primary_entity_name":"Bionano Genomics, Inc."},"word_count":384,"has_tables":true,"body_markdown":"Item 5.07 Submission of Matters to a Vote of Security Holders.\n\nOn May 14, 2026, Bionano Genomics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). As of March 19, 2026, the record date for the Annual Meeting (the “Record Date”), 11,091,615 shares of the Company’s common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below.\n\nA total of 4,225,995 shares of the Company’s common stock were present at the Annual Meeting in person, by virtual attendance, or by proxy, which represents approximately 38.1% of the shares of the Company’s common stock outstanding and entitled to vote at the Annual Meeting as of the Record Date.\n\n \n\nProposal 1. Election of Directors.\n\nThe Company’s stockholders elected the two persons listed below as Class II Directors, each to serve until the Company’s 2029 Annual Meeting of Stockholders or until their successors are duly elected and qualified or until their earlier death, resignation or removal. The final voting results were as follows:\n\n \n\nName\n\nVotes For\n\nVotes Withheld\n\nBroker Non-Votes\n\nAlbert Luderer, Ph.D.\n\n \n\n847,601\n\n \n\n143,790\n\n \n\n3,234,604\n\nKristiina Vuori, M.D., Ph.D.\n\n \n\n867,474\n\n \n\n123,917\n\n \n\n3,234,604\n\nProposal 2. Approval, on an Advisory Basis, of the Compensation of the Company’s Named Executive Officers.\n\nThe Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s definitive proxy statement relating to the Annual Meeting. The final voting results were as follows:\n\n \n\nVotes For\n\nVotes Against\n\nAbstentions\n\nBroker Non-Votes\n\n697,999\n\n \n\n216,553\n\n \n\n76,839\n\n \n\n3,234,604\n\nProposal 3. Ratification of the Selection of Independent Registered Public Accounting Firm.\n\nThe Company’s stockholders ratified the selection of BDO USA, P.C. by the Audit Committee of the Board of Directors as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results were as follows:\n\n \n\nVotes For\n\nVotes Against\n\nAbstentions\n\nBroker Non-Votes\n\n3,770,715\n\n \n\n206,541\n\n \n\n248,739\n\n \n\n—\n\n \n\n \n\n \n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.\n\n \n\n \n\nBionano Genomics, Inc.\n\n \n\n \n\n \n\n \n\nDate: May 14, 2026\n\nBy:\n\n/s/ Albert A. Luderer, Ph.D.\n\n \n\n \n\nAlbert A. Luderer, Ph.D.\n\n \n\n \n\nInterim Chief Executive Officer"}